Abstract:Background. Early identification of patients with severe coronavirus disease (COVID-19) at an increased risk of progression may promote more individualized treatment schemes and optimize the use of medical resources. This study is aimed at investigating the utility of the C-reactive protein to albumin (CRP/Alb) ratio for early risk stratification of patients. Methods. We retrospectively reviewed 557 patients with COVID-19 with confirmed outcomes (discharged or deceased) admitted to the West Court of Union Hospital, Wuhan, China, between January 29, 2020 and April 8, 2020. Patients with severe COVID-19 ( n = 465 ) were divided into stable ( n = 409 ) and progressive ( n = 56 ) groups according to whether they progressed to critical illness or death during hospitalization. To predict disease progression, the CRP/Alb ratio was evaluated on admission. Results. The levels of new biomarkers, including neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, CRP/Alb ratio, and systemic immune-inflammation index, were higher in patients with progressive disease than in those with stable disease. Correlation analysis showed that the CRP/Alb ratio had the strongest positive correlation with the sequential organ failure assessment score and length of hospital stay in survivors. Multivariate logistic regression analysis showed that percutaneous oxygen saturation (SpO2), D-dimer levels, and the CRP/Alb ratio were risk factors for disease progression. To predict clinical progression, the areas under the receiver operating characteristic curves of Alb, CRP, CRP/Alb ratio, SpO2, and D-dimer were 0.769, 0.838, 0.866, 0.107, and 0.748, respectively. Moreover, patients with a high CRP/Alb ratio (≥1.843) had a markedly higher rate of clinical deterioration ( log − rank p < 0.001 ). A higher CRP/Alb ratio (≥1.843) was also closely associated with higher rates of hospital mortality, ICU admission, invasive mechanical ventilation, and a longer hospital stay. Conclusion. The CRP/Alb ratio can predict the risk of progression to critical disease or death early, providing a promising prognostic biomarker for risk stratification and clinical management of patients with severe COVID-19.

Serum interleukin-6, procalcitonin, and C-reactive protein at hospital admission can identify patients at low risk for severe COVID-19 progression

Serum IL-6 and Procalcitonin Are Two Promising Novel Biomarkers for Evaluating the Severity of COVID-19 Patients.

Baseline Interleukin-6 Level Predicts Risk of Severe COVID-19: A Two-Center, Retrospective Study

Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19

Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study

Serum cytokine dysregulation signatures associated with COVID-19 outcomes in high mortality intensive care unit cohorts across pandemic waves and variants

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients

The Role of SARS-CoV-2 Nucleocapsidic Antigen and Krebs von den Lungen 6 Serum Levels in Predicting COVID-19 Pneumonia Outcome

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

Serum biomarkers for prediction of mortality in patients with COVID-19

Identification of parameters in routine blood and coagulation tests related to the severity of COVID-19

An inflammatory cytokine signature predicts COVID-19 severity and survival

Prognostic value of ANDC score and CRP-derived inflammatory markers in hospitalized adult patients with COVID-19

Longitudinal Profile of Laboratory Parameters and Their Application in the Prediction for Fatal Outcome Among Patients Infected With SARS-CoV-2: A Retrospective Cohort Study

Prognostic peripheral blood biomarkers at ICU admission predict COVID-19 clinical outcomes

Cytokines and Other Laboratory Parameters of Hospitalized COVID-19 Patients that Predict Intensive Care Unit Admission

Early Prediction of Disease Progression in Patients with Severe COVID-19 Using C-Reactive Protein to Albumin Ratio

Non-Conventional Prognostic Markers in Life-Threatening COVID-19 Cases—When Less Is More

Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19

Early and accurate prediction of COVID-19 hospitalization risk and symptomatic course of SARS-CoV-2 infection